.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median consequence of 11 months, clients along with metastatic stomach lumps who obtained biomarker-matched therapies based on circulating tumor DNA profiling showed a greater medical advantage than those getting unparalleled treatment.